Jounce Therapeutics

CURRENT OPENINGS

We are looking for exceptional individuals who share our passion and perseverance for developing highly durable cancer immunotherapies that can dramatically impact and improve patients’ lives.

New team members will add to Jounce’s growing in-house expertise, as we continue to grow and evolve, while focusing on cultivating a positive, productive and satisfying work environment.

 

 

View all open positions or use the following search form to find jobs that suit your specific career interests.


The system cannot access your location for 1 of 2 reasons:
  1. Permission to access your location has been denied. Please reload the page and allow the browser to access your location information.
  2. Your location information has yet to be received. Please wait a moment then hit [Search] again.


Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and aiming to provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce’s internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce’s most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce’s broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. All applicants should be legally entitled to work for any employer in the U.S.

Note to Employment Agencies: Please do not forward any agency resumes. The company will not be responsible for any fees related to resumes that are unsolicited.



Job Seekers: Protect Yourself Against Identity Theft

Please be aware there are instances of identity thieves in our industry posting company-branded jobs and posing as employees in an attempt to steal personal information from job seekers. They visit job-related websites and invite candidates to online chats. During the chat, they press job seekers to provide bank account information and personal identification numbers. If you receive unexpected offers of employment from people claiming to work for Jounce, we suggest you do not correspond with them. Do not click any hyperlinks and do not open an attachments.

At Jounce, we do not ask for personal financial information at any point in the application or interview process including during telephone, in-person or video interviews nor do we charge job seekers fees as part of the recruitment process. Jounce's recruiting correspondence will be sent by a recruiting representative with @jouncetx.com e-mail address – not @joinjouncetx.com, @gmail.com, @yahoo.com, @hotmail.com or any other e-mail domain service.

Should you encounter this issue, consider the following actions: 1) If in the U.S., place a freeze on your credit reports: https://consumer.ftc.gov/articles/what-know-about-credit-freezes-fraud-alerts ; 2) file a complaint with the U.S. Federal Trade Commission: https://www.ftccomplaintassistant.gov ; and/or 3) file a report with your local law enforcement agency immediately.